The nightmare is almost over. Until recently, there was a diagnosis infectious peritonitis in cats death sentence. Either a slow, persistent decline, or a decision to euthanize and end suffering. This happened to about 1% cats, mostly still kittens.
It was later found that certain antiviral drugs they can not only improve the symptoms, but can even lead tocure. But there was still a problem.
These antivirals were not licensed in Australia and therefore their import and use were illegal. The only cats that survived were therefore those whose owners and veterinarians were willing to take risks. My own veterinary association despite evidence of treatment effectiveness strongly warned against using them.
All the problems are over today.
Remdesivir: A new hope for the FIP
You must have heard of remdesivir. It was promptly approved by the TGA and the FDA due to promising results in the treatment of COVID-19. Importantly for remdesivire is that it is almost identical to black market drugs such as GS-441524.
It is now freely available with a valid prescription and meets all the strict criteria we expect from licensed drugs. Veterinarians still need to warn you that this is an off-label treatment, but it is the same as other cases where we use a human drug for treatment (which is often the case!).
Preliminary testing in Sydney has yielded excellent results. So now we have a cure for everyone. I estimate that fewer than 5% cats with FIP are currently undergoing treatment. Now all cat owners are offered a chance for treatment and most will seize it, although the cost problem still exists.
The cost of using remdesivir in cats
As you can imagine, it is an expensive medicine. I estimate that the 80-day treatment will cost around $ 4,800.
Is a however, this is very similar to the prices people currently pay for GS-441524 from the black market with unproven purity or efficiency. This time, if the cat is insured, it is likely that the treatment will even be covered by the insurance company.
Based on our previous observations, 84-day treatment should cure most affected cats. It is given as a subcutaneous injection once a day, but don't be put off. Everyone can do it and we will be happy to show you how.
Advice on the use of remdesivir for veterinarians
Australian veterinarians reading this article can contact me about a document that contains the recommended dosage, protocols based on the symptoms of the disease and how to obtain the drug itself. See the comments section below for some dosing notes. (translator's note - click on the link leading to the original article).
We are all committed to the work of Dr. Richard Malik DVSc PhD FACVSc FASM and the Feline Diseases Research Team at my alma mater The University Of Sydney.
We also thank the volunteer groups that helped many cats regain their health by taking risks. Their work is complete and we are grateful.
Andrew Spanner BVSc (Hons) MVetStud, a veterinarian in Adelaide, Australia. These blogs come from a series of regularly published e-mails and Twitter. Sign in to subscribe regularly so you never miss a story!
Feline peritonitis (FIP) is a virus-induced, immune-mediated feline disease caused by virulent feline coronavirus biotypes (FCoV), known as feline infectious peritonitis virus (FIPV). Historically, three major pharmacological approaches have been used to treat FIP: (1) immunomodulators to non-specifically stimulate the patient's immune system to attenuate the clinical effects of the virus through a strong immune response, (2) immunosuppressive agents to temporarily suppress clinical symptoms, and (3) human antiviral medicines originally intended for other purposes, none of which have unfortunately not been reliably demonstrated to be effective in the treatment of FIPV. Recent studies investigating the broad-spectrum coronavirus protease inhibitor GC376 and the adenosine nucleoside analog GS-441524 have shown that they have led to increased survival and clinical cure in many patients. However, doctors' access to these antiviral therapies is currently problematic because they have not yet obtained registration for veterinary use. As a result, FIP treatment remains a major challenge. The purpose of this summary is to provide information on the current status of therapeutics for the treatment of FIP. Furthermore, due to the increased interest in coronaviruses resulting from the current human pandemic, this summary also provides information on domestic cats identified as positive for SARS-CoV-2.
Feline infectious peritonitis (FIP) is a virus-induced, immune-mediated disease with a high mortality rate that globally affects domestic cats as well as some wild cats (Addie et al. 2009; Drechsler et al. 2011; Pedersen 2014a). The disease is caused by virulent feline coronavirus (FCoV) biotypes, known as feline infectious peritonitis virus (FIPV) (Addie et al. 2009; Drechsler et al. 2011; Pedersen 2014a). FIPV is caused by unidentified genetic changes in FCoV, leading to an increased ability to replicate in monocytes and macrophages (Addie et al. 2009; Pedersen 2009). Although FIP can affect cats of any age, it is most common in cats less than three years of age, especially in cats aged four to sixteen months (Addie et al. 2009; Pedersen 2009). The true prevalence of FIP is unknown. While some authors report that approximately 12%, or one in nine FCoV-infected cats, develop clinical signs of FIP (Addie et al. 2009; Pedersen 2014b), this figure was extrapolated from veterinary clinic studies rather than from domesticated feline population as a whole and does not correspond to field estimates of the number of recorded cases in relation to the population. Other studies provide a lower prevalence of FIP. In a control study lasting ten years from 1986 to 1995, out of 397,182 additions presented to North American Veterinary Teaching Hospitals, approximately 0.55% new cats and 0.36% of the total number of cats were FIP cats (Rohrbach et al., 2001). These patients with FIP were significantly more likely to be purebred, young, and sexually intact males (Rohrbach et al. 2001; Pesteanu-Somogyi et al. 2006). In a study of cat growth at North Carolina State University College of Veterinary Medicine over a 16-year period from 1986 to 2002 from 11,535 cats of known breed, the prevalence of suspected or confirmed FIP in the mixed cat population was 0.35% versus 1.3% in the population. purebred cats (Pesteanu-Somogyi et al. 2006). In some of these studies, the diagnosis of FIP was made on the basis of clinical examination alone and without confirmatory diagnostic tests (Rohrbach et al. 2001; Pesteanu-Somogyi et al. 2006). In an Australian study, young cats were significantly overrepresented among FIP cases (Worthing et al. 2012). Compared to the Australian cat population, domestic crossbred, Persian and Himalayan cats were significantly under-represented, while several breeds were over-represented, including British Shorthair, Devon Rex and Abyssinian cat. A significantly higher proportion of FIP was observed in males (Worthing et al. 2012).
FIP is categorized according to clinical manifestation as either a wet (effusive) or dry (non-fusible) form (Addie et al. 2009; Pedersen 2009, 2014a). The wet form is characterized by immune-mediated fibrinous-granulomatous serositis, often with protein-rich effusions in the thoracic or abdominal cavity (Addie et al. 2009; Pedersen 2009, 2014a). In contrast, the dry form is typical of pyogranulomatous lesions found in multiple body organs and around blood vessels (Addie et al. 2009; Pedersen 2009, 2014a).
FIP-related mortality is extremely high as soon as clinical signs appear (Pedersen 2014b). As Pedersen noted (2014b, p. 1333), "the onset of visible manifestations of the disease is a signal that the cat's fight with the virus is lost." Although some cats may live with FIP for weeks, months, or sometimes years (Pedersen 2014b), times survival generally varies from days to weeks for effusive FIP and weeks to months for nonfusion (dry) FIP (Fischer et al. 2011; Tsai et al. 2011; Hugo and Heading 2015). Determining the definitive ante-mortem diagnosis of FIP is challenging, especially since current diagnostic tests fail to distinguish between FCoV and FIPV (Fischer et al. 2011; Pedersen 2014b). Because the confirmed diagnosis relies on positive immunostaining of the FCoV antigen in cytology and histopathology, invasive diagnostic tests for tissue biopsies may be required in sick cats to confirm the diagnosis. (Tasker 2018). We refer the reader to a recent summary of more detailed information on FIP diagnostics (Drechsler et al. 2011; Pedersen 2014b; Tasker 2018; Kennedy 2020). In exploring treatment options for FIP, many older studies describing potential treatment are mostly based on cases without a confirmed diagnosis of FIP and suffering from a lack of properly controlled clinical trials (Hartmann and Ritz 2008). Also, the use of other reported treatment options is currently only supported by in vitro studies and not by in vivo clinical studies (Choong et al. 2014; Doki et al. 2016; Hu et al. 2017; Takano et al. 2017). Despite recent antiviral studies with GC376 and GS-441524, which hold great promise in the treatment of FIPV in naturally and experimentally infected cats (Murphy et al. 2018; Pedersen et al. 2018, 2019), these substances have not yet been authorized for veterinary use (Wogan 2019a, 2019b). Therefore, there is currently no effective treatment for FIP (Pedersen 2019a) legally available to veterinarians.
2. SARS-CoV-2
We are currently witnessing great interest in the potential of type 2 severe acute respiratory syndrome virus (SARS-CoV-2) to infect animals, including reports of domesticated and zoologous wild cat farms with a positive result for this virus (Hosie et al. 2020; USA). Ministry of Agriculture 2020; Wang et al. 2020). Coronaviruses are single-stranded RNA viruses (Lundstrom 2020) classified into four genera based on genotypic and serological characterization (Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus; Woo et al. 2012). While FCoV is an alpha-coronavirus (Felten and Hartmann 2019), SARS-CoV-2, which causes COVID-19, is a beta-coronavirus (Chakraborty and Maity 2020; Lai et al. 2020). Coronaviruses have a high recombination rate as well as inherently high mutation rates, which allow them to adapt rapidly with an increased potential to infect new hosts (Woo et al. 2006). Viral recombination is mediated in part by the corrective activity of nsp14 exoribonuclease, which has previously been shown to inhibit the development of nucleoside-based coronavirus treatment (Agostini et al. 2018).
Domesticated cats that tested positive for SARS-CoV-2 were associated with SARS-CoV-2 positive or suspected SARS-CoV-2 owners (Halfmann et al. 2020; Newman 2020). A small number of domesticated SARS-CoV-2-positive cats showed upper or lower airway respiratory symptoms (Sailleau et al. 2020), while others did not show obvious clinical symptoms (Newman 2020; Sailleau et al. 2020; Sit 2020; Sit et al. 2020). Limited experimental studies involving a large number of viral vaccines have shown that cats can transmit SARS-CoV-2 to other cats housed in the same facility by air (Shi et al. 2020). Another study reported that vaccination and exposure to SARS-CoV-2 lead to nasal excretion in cats, and that cats without clinical signs are capable of direct virus transmission to other cats (Halfmann et al. 2020). There is currently no evidence that cats can transmit SARS-CoV-2 to humans (Hosie et al. 2020).
As some of the antivirals described below have shown some anti-FCoV efficacy, it is tempting to extrapolate that they may also reduce SARS-CoV-2 excretion in rare cases of feline infection. However, to the best of the authors' knowledge, no in vivo studies have been published to verify their antiviral activity in SARS-COV-2 in cats.
3. FIP therapeutics
In practice, three main approaches are used to treat FIP, either individually or in combination (Pedersen 2014b). The first approach seeks to non-specifically modulate the patient's immune system in order to reduce the clinical effects of the virus through a strong immune response (Pedersen 2014b). The second approach relies on the use of immunosuppressive drugs to suppress the inflammatory response that is at the core of the pathology of the disease (Hartmann and Ritz 2008; Addie et al. 2009; Pedersen 2014b), while the third approach focuses on the use of antiviral agents that inhibit virus replication (Murphy et al., 2018; Pedersen et al., 2018, 2019). Although each of these main approaches can be used simultaneously, we will address each of them in turn.
3.1. Non-specific immunostimulants
Non-specific immunostimulants have been used to treat FIP for many years, often due to unsubstantiated reports that these treatment regimens can either prolong survival or serve as a direct cure for FIP (Pedersen 2014b). The main goal of this approach is to stimulate the patient to develop an immune response strong enough to reduce the viral load sufficiently to suppress the clinical manifestations of the infection. However, it is somewhat paradoxical that the use of immunostimulants is often associated with immunosuppressants, as some of these drugs may be mutually supportive (Pedersen 2014b). Examples of non-specific immunostimulants used to treat FIP include staphylococcal A protein (Pedersen 2014b), Propionibacterium acnes (an immunomodulatory compound derived from gram-positive bacteria) (Weiss et al. 1990), T-cell immunomodulators (such as omega [ω] interferon). ) and plant extracts such as polyprenyl immunostimulant (PI) (Legendre and Bartges 2009; Legendre et al. 2017). All of these substances were unsuccessful or had only a limited effect in the treatment of FIP. For example, with respect to the biological plant extract PI, the use of this agent was originally proposed by Legendre and Bartges (2009) after three cats were reportedly cured of the dry form of FIP after long-term treatment with PI. However, these studies admit that treatment had no effect in cats with more severe FIP (Legendre and Bartges 2009). A later PI field study in 60 cats showed prolonged survival, with four of these cats surviving more than 300 days with improved quality of life (Legendre et al. 2017). The study also showed that PI survival times were significantly longer in cats that were not co-treated with corticosteroids (Legendre et al. 2017).
3.2. Immunosuppressive agents
The use of immunosuppressive agents to suppress the inflammatory response in FIPV is something of a therapeutic surrogate. This means that the lack of access to safe and effective alternatives leaves veterinarians with very few options other than relying on immunosuppressive therapy to suppress the clinical signs of FIP (Hartmann and Ritz 2008; Addie et al. 2009; Pedersen 2014a). Examples of immunosuppressive agents in the treatment of FIP include glucocorticoids (e.g., prednisolone, dexamethasone) (Disque et al. 1968; Addie et al. 2009), cytokine inhibitors (e.g., pentoxifylline and propentophyllin) (Fischer et al. 2011), and alkylating agents (Fischer et al. 2011). e.g., cyclophosphamide) and chlorambucil) (Bilkei 1988; Addie et al. 2009). Although glucocorticoid administration reduces clinical signs in cats with FIP, there is no evidence that they have any therapeutic effect in infected cats (Addie et al. 2009). Claims that substances such as glucocorticoids are effective against FIP have been refuted by placebo-controlled, double-blind studies by Ritz et al. (2007) and Fischer et al. (2011). In these studies examining the effects of feline interferon ω (Ritz et al. 2007) and propentofylline (Fischer et al. 2011) on the survival and quality of life of FIP-affected cats, all cats (including those in the placebo group) received dexamethasone and / or prednisolone. The authors reported that there was no significant difference in survival between cats with FIP that received either feline interferon ω (Ritz et al. 2007) or propentophyllin (Fischer et al. 2011) (median survival time of cats interferon ω and eight days for propentophylline) and those in the control group given glucocorticoids alone (median survival of eight days in both studies). Due to the co-administration of dexamethasone and / or prednisolone in both of these studies, it is difficult to determine the effects of feline interferon ω or propentofylline as the sole therapeutic agent. Feline interferon ω has been shown to inhibit FCoV replication in vitro (Mochizuki et al. 1994). An uncontrolled study with feline interferon ω and glucocorticoids yielded a promising result in 67% cats that achieved complete or partial remission, but FIP was not confirmed in these cases (Ishida et al. 2004). When recombinant human leukocyte interferon alpha or feline fibroblast beta interferon was used alone, neither reduced mortality in treated cats compared to controls (Weiss and Toivio-Kinnucan 1988; Bolcskei and Bilkei 1995; Ritz et al. 2007). However, when a high dose of alpha interferon was used in combination with Propionibacterium acnes, the average survival time was prolonged, but only by three weeks (Weiss et al. 1990). Although interferons are often used in cats with FIP, their effectiveness is questionable. The use of cyclophosphamide in combination with prednisolone and ampicillin has also been studied in cats with FIP (Bilkei 1988). Seventy-six of the 151 cats were considered "healthy" after treatment. However, the cats included in this study did not have a reliably confirmed diagnosis of FIP. Another study investigating the use of cyclophosphamide other than prednisolone and ampicillin in cases of suspected FIP states that 29-80% cats died within three years (Bolcskei and Bilkei 1995). Again, however, FIP was not confirmed in these cats. Ozagrel hydrochloride (a thromboxane synthesis inhibitor) has also been used as an immunosuppressive agent against FIP (Watari et al. 1998). Although two cats have shown beneficial effects, FIP has not been confirmed in either of them (Watari et al. 1998).
3.3. Specific FIP therapeutics
A third approach to FIP treatment involves the administration of antiviral agents targeting either the cellular mechanisms that viruses choose to replicate or, alternatively, a specific aspect of virus activity associated with infection and / or replication (Hartmann and Ritz 2008; Addie et al. 2009; Pedersen 2014a ). Antiviral drugs that inhibit FCoV have been identified, but many have not been successful in infected patients (Weiss et al. 1993; Hartmann and Ritz 2008; Addie et al. 2009; McDonagh et al. 2014; Pedersen 2014b). However, a new therapeutic breakthrough has emerged using the nucleoside analog GS-441524 with a direct effect on FIP virus (Murphy et al. 2018; Pedersen 2019a, 2019b; Dickinson et al. 2020). GS-441524, the active metabolite of remdesivirus, is a terminator of the RNA strand of viral RNA-dependent RNA polymerase (Murphy et al. 2018; Pedersen et al. 2019). naturally occurring FIP (Murphy et al. 2018; Pedersen et al. 2019). Using an in vitro approach, Murphy et al. (2018) determined that GS-441524 did not show toxicity in feline Crandell Rees (CRFK) kidney cells at concentrations of 100 μM, while still able to inhibit FIPV replication in cultured CRFK cells even in naturally infected feline peritoneal macrophages at 1.0 µM concentrations. . In an accompanying in vivo study in FIPV experimentally infected cats (FIPV serotype I strain m3c-2), GS-441524 was administered once daily (5.0 mg / kg BW or 2.0 mg / kg BW as a subcutaneous injection [SC]) after for two weeks (Murphy et al. 2018). This regimen, which required at least two weeks of treatment, resulted in a rapid reversal of clinical symptoms and a return to normal in all patients. No toxicity was observed. Based on this work, Pedersen et al. (2019) investigated the in vivo therapeutic effects of GS-441524 on naturally occurring FIP, including both wet and dry forms of the disease. 31 cats (26 with FUS and 5 with non-fusion FIP) were enrolled in this study and given a dose of 2.0 mg / kg BW SC once daily for at least 12 weeks. The dose was increased to 4.0 mg / kg BW SC once daily as indicated by worsening clinical symptoms. Four cats were euthanized or died during the first five days of the experiment due to the severity of their infection. The fifth cat was euthanized after 26 days due to the lack of response to treatment. The remaining 26 cats successfully completed a twelve-week (or longer) cycle. Eighteen cats remained healthy after one treatment cycle, while the remaining eight relapsed within 3 to 84 days. Three of the eight relapsing cats were treated again with the same dose, while the five cats had their dose increased from 2.0 to 4.0 mg / kg body weight. Five cats treated with the higher dose recovered. Of the remaining three cats treated with the original lower dose, two relapsed a second time and required a third treatment with a higher dose. The two cats recovered. The third cat relapsed after the second round of the lower dose and was sacrificed due to the severity of its neurological disease. The study yielded 25 long-term surviving cats. The most common side effect was injection site reactions (Pedersen et al. 2019). Based on these findings, the authors concluded that GS-441524 is a safe and effective treatment for FIP when administered at a dose of 4.0 mg / kg BW SC once daily for at least 12 weeks (Pedersen et al. 2019). For neurological cases of FIP, a higher dose of 5.0 to 10.0 mg / kg BW SC once daily for 12 weeks was recommended, resulting from the treatment of four clinical cases (Dickinson et al. 2020). Due to the consistency of its reported effectiveness, a growing global black market has emerged with GS-441524, as it has not been formally approved for commercial use anywhere (Pedersen 2019b). Interestingly, GS-441524 also showed in vitro antiviral activity against SARS-CoV (Cho et al. 2012).
Remdesivir (GS-5734), a prodrug of the original adenosine nucleoside analog, GS-441524 (Amirian and Levy 2020), has been approved by the US Food and Drug Administration (FDA) for emergency use in the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults. and children hospitalized with a severe infection. This emergency approval was based on a randomized, double-blind, placebo-controlled study conducted by the National Institute of Allergies and Infectious Diseases (NIAID) (NCT04280705) and a sponsored open-label study evaluating the different duration of remdesivir (NCT04292899). Another randomized, double-blind, placebo-controlled, multicenter study conducted in China also showed that the use of remdesivir in adult patients with COVID-19 was associated with shortened clinical improvement time with early treatment, although no statistically significant clinical benefits were observed (Wang et al. 2020). Clinical trials of remdesivir and many other antiviral drugs for the treatment of COVID-19 are currently underway in many countries (Amirian and Levy 2020).
Although not related to direct treatment of FIP, a drug designed to reduce FCoV excretion may be a likely precursor to FIP prevention. An antiviral product called Mutian® X, a synthetic adenosine analogue whose exact composition is a "trade secret", has been shown to stop fecal coronavirus excretion in chronically infected cats when administered orally at a dose of 4.0 mg / kg body weight once daily. for four days (Addie et al. 2020). Addie et al. (2020) suggest that the combination of probiotics and interferon in the same study reduced coronavirus secretion in two cats. Feline interferon ω has been shown to reduce feline coronavirus viral secretion in retrovirus-infected cats (Gil et al. 2013).
3.4. Other antiviral compounds
Other candidate compounds have also been tested for their antiviral activity against FIPV. For example, antiviral ribavirin has been tested in vivo in cats experimentally infected with FIPV and has been found to have marginal antiviral activity against FIPV and toxicity to cats (Weiss et al. 1993). Cyclosporin A, a cyclophilin inhibitor, has been shown to inhibit feline coronavirus replication in vitro, although the mechanism of its inhibitory effects is unknown (Pfefferle et al. 2011; Tanaka et al. 2012, 2013). Cyclosporine was administered to one cat with effusion FIP, and a decrease in pleural fluid volume and viral load was noted after treatment. The cat died of respiratory failure on day 264, but the cause of death has not been determined (Tanaka et al. 2015). Likewise, two compounds, galanthus nivalis agglutinin (GNA) and nelfinavir (protease inhibitor), were able to inhibit FCoV replication in vitro when combined (Hsieh et al. 2010). Nevertheless, none of these compounds proved to be effective when tested under conditions simulating FIPV infection. Similarly, based on promising findings regarding the efficacy of 3C-like protease inhibitors against FCoV (Kim et al. 2013, 2015, 2016), a field study was performed with GC376 in 20 cats with various forms of FIP, except those with neurological symptoms (Pedersen et al., 2018). Cats were dosed with 15.0 mg / kg BW, SC, twice daily for a minimum of 12 weeks. Although the results were encouraging (seven cats achieved an average disease remission of 11.2 months), side effects occurred, including transient injection pain, subcutaneous fibrosis, alopecia, and abnormal permanent tooth development in cats treated before 16-18. by week of age (Pedersen et al. 2018). There are other protease inhibitors targeting the 3C-like protein of coronaviruses (Rathnayake et al. 2020; Theerawatanasirikul et al. 2020).
The antifungal itraconazole demonstrated in vitro anti-FIPV activity at low drug concentrations (2.5 μM) (Takano et al. 2019). A recent in vivo study examined the effects of a combination of itraconazole (50 mg / animal orally, once daily) and an anti-human TNF-alpha monoclonal antibody (10 mg / animal) on the treatment of three cats experimentally infected with FIPV (Doki et al. 2020). Although two of the three cats showed improvement in FIPV-related clinical symptoms, an increase in peripheral blood lymphocytes and a decrease in alpha-1-acid glycoproteins were observed after initiation of treatment. A third cat was killed for not responding to treatment. The authors concluded that this combination of drugs may be useful until more effective anti-FIPV agents are available. Itraconazole was used in combination with prednisolone to treat effusion FIP in a three-month-old Scottish Fold kitten, resulting in a reduction in pleural effusion (Kameshima et al. 2020). However, this cat showed neurological manifestations and was euthanized due to status epilepticus after 38 days of treatment (Kameshima et al. 2020). Other agents, including anti-feline TNF-alpha monoclonal antibody, have also been shown to have antiviral activity against FCoV (Doki et al. 2016); U18666A (cholesterol transport inhibitor) (Takano et al. 2017; Doki et al. 2020); difylline (vacuolar ATPase blocker) and its nanoformulation (Hu et al. 2017) and a circular triple helix forming oligonucleotide RNA (Choong et al. 2014). However, no in vivo studies using these compounds have been published.
The human antimalarial drug chloroquine also inhibits FIPV replication in vitro (Takano et al. 2013; McDonagh et al. 2014). Chloroquine has long been known to have anti-inflammatory and in vitro antiviral properties against a wide range of viruses (Takano et al. 2013). Despite good in vitro activity, chloroquine showed weak antiviral activity against in vivo experimentally induced FIP infection (Takano et al. 2013). In their study, Takano et al. (2013) found that chloroquine treatment was associated with improved clinical scores and a slightly increased but not statistically significant survival time of cats infected with highly virulent FCoV FIPV 1146. Further increased levels of alanine aminotransferase activity in the chloroquine-treated groups indicated a potential liver damage problem. A dose of 10 mg / kg body weight twice weekly SC was extrapolated from human dosing protocols and was not based on any known pharmacokinetic studies in cats. The antiviral activity of hydroxychloroquine against FIPV has also recently been the subject of an in vitro study. When hydroxychloroquine was used with recombinant feline IFN-ω, it showed increased antiviral activity against FIPV infection (Takano et al. 2020). Hydroxychloroquine has also been studied in clinical trials for the treatment of COVID-19 in humans (Lundstrom 2020). However, this drug has yielded controversial results, leading to the current conclusion that its clinical efficacy in patients with COVID-19 has not been established (Lundstrom 2020).
McDonagh et al. (2014) examined 19 candidate compounds used in the treatment of other coronavirus infections for their cellular toxicity and efficacy in inhibiting FIPV replication in infected CRFK cells. In this in vitro study, a resazurin-based cytopathic effect inhibition (CPE) screening assay was developed to determine antiviral activity against two FCoV strains: FECV 1683 and FIPV 1146. Other assays, including plaque reduction, reduction in virus excretion, and viricidal suspension, were used to evaluate the antiviral effects of candidate compounds. The study finally identified three compounds (chloroquine, mefloquine and hexamethylene amiloride) that significantly reduced FIPV viral load in infected CRFK cells without cytotoxic effects at 10 μM concentrations. In addition, preliminary experiments suggest that the antiviral mechanisms of all three compounds act at an early stage of viral replication.
Due to the potential impact of these results on the treatment of FIP, further investigation of these compounds is needed (McDonagh et al. 2014). Both chloroquine and mefloquine are commercially available pharmaceuticals registered for use in humans. Behind each of them is a wealth of supporting literature on their pharmacokinetics and safety in non-feline species. Some information on the pharmacokinetic profile of mefloquine in cats is already available (Izes 2019; Izes et al. 2020a, 2019, 2020b; Yu et al. 2020). Hexamethylene amiloride is significantly less known, especially with regard to its safety (McDonagh et al. 2014). Since Takano et al. (2013), who previously questioned the in vivo efficacy of chloroquine against FIP, consider clinical trials of mefloquine for the treatment of infected cats. Recent in vitro pharmacokinetic studies have suggested that mefloquine undergoes phase I hepatic metabolism but not phase II glucuronidative metabolism when catalysed by feline liver microsomes and is therefore unlikely to cause delayed elimination in cats (Izes et al. 2020a). The pharmacokinetic profile of mefloquine in cats has been investigated in anticipation of clinical studies to inhibit feline coronavirus and feline calicivirus in cats clinically affected by these viral infections (Yu et al. 2020). Further studies of the clinical efficacy of mefloquine in FIP-confirmed cats are ongoing.
With respect to all of these antiviral agents, it is important to note that it may be necessary to administer a combination of therapeutics to inhibit the selection of viral resistance in monotherapy.
4. Conclusion
Despite the lack of their commercial availability, antiviral agents such as GS-441524 and GC376 have been shown to be effective treatment options for FIP. While pending approval of these substances, other commercially available substances, such as mefloquine and itraconazole, need to be further investigated through in vivo studies to determine their true potential as antivirals for the treatment of FIPV. In addition, while the current SARS-CoV-2 pandemic has been of little benefit to veterinary medicine, One Health's global approach tells us the need to monitor therapeutic progress in the fight against coronaviruses, as information may ultimately be useful among species.
References
Addie D, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lloret A, Lutz H, et al. . 2009. Feline infectious peritonitis. ABCD guidelines on prevention and management. J Feline Med Surg. 11 (7): 594–604. [PMC free article] [PubMed] [Google Scholar]
Addie DD, Curran S, Bellini F, Crowe B, Sheehan E, Ukrainchuk L, Decaro N .. 2020. Oral Mutian® X stopped faecal feline coronavirus shedding by naturally infected cats. Res Vet Sci. 130: 222–229. [PMC free article] [PubMed] [Google Scholar]
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, et al. . 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 9 (2): e00221-18. [PMC free article] [PubMed] [Google Scholar]
Amirian ES, Levy JK .. 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 9: 100128. [PMC free article] [PubMed] [Google Scholar]
Bilkei G. 1988. Contribution to FIP therapy. Tierärztl Umschau. 43: 192–196. [Google Scholar]
Bolcskei A, Bilkei G .. 1995. Langzeitstudie iiber behandelte FIP-verdachtige katzen. Tierarztliche Umschau. 50: 721–728. [Google Scholar]
Chakraborty I, Maity P .. 2020. COVID-19 outbreak: migration, effects on society, global environment and prevention. Sci Total Environ. 728: 138882. [PMC free article] [PubMed] [Google Scholar]
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Feng JY, Ray AS, Kim CU .. 2012. Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9- dideazaadenosine C-nucleosides. Bioorg Med Chem Lett. 22 (8): 2705–2707. [PMC free article] [PubMed] [Google Scholar]
Choong OK, Mehrbod P, Tejo BA, Omar AR .. 2014. In vitro antiviral activity of circular triple helix forming oligonucleotide RNA towards feline infectious peritonitis virus replication. Biomed Res Int. 2014: 654712. [PMC free article] [PubMed] [Google Scholar]
Dickinson PJ, Bannasch M, Thomasy SM, Murthy VD, Vernau KM, Liepnieks M, Montgomery E, Knickelbein KE, Murphy B, Pedersen NC, et al. . 2020. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. J Vet Intern Med. 34 (4): 1587–1593. [PMC free article] [PubMed] [Google Scholar]
Disque D, Case M, Youngren J .. 1968. Feline infectious peritonitis. J Am Vet Med Assoc. 152 (4): 372–375. [PubMed] [Google Scholar]
Doki T, Takano T, Kawagoe K, Kito A, Hohdatsu T .. 2016. Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis. Res Vet Sci. 104: 17–23. [PMC free article] [PubMed] [Google Scholar]
Doki T, Tarusawa T, Hohdatsu T, Takano T .. 2020. In vivo antiviral effects of U18666A against type I feline infectious peritonitis virus. Pathogens. 9 (1): 67. [PMC free article] [PubMed] [Google Scholar]
Doki T, Toda M, Hasegawa N, Hohdatsu T, Takano T .. 2020. Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis. Arch Virol. 165 (5): 1110–1197. [PMC free article] [PubMed] [Google Scholar]
Drechsler Y, Alcaraz A, Bossong FJ, Collisson EW, Diniz PPVP .. 2011. Feline coronavirus in multicat environments. Vet Clin North Am Small Anim Pract. 41 (6): 1133–1169. [PMC free article] [PubMed] [Google Scholar]
Felten S, Hartmann K .. 2019. Diagnosis of feline infectious peritonitis: a review of the current literature. Viruses. 11 (11): 1068. [PMC free article] [PubMed] [Google Scholar]
Fischer Y, Ritz S, Weber K, Sauter-Louis C, Hartmann K .. 2011. Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 25 (6): 1270–1276. [PMC free article] [PubMed] [Google Scholar]
Gil S, Leal RO, Duarte A, McGahie D, Sepúlveda N, Siborro I, Cravo J, Cartaxeiro C, Tavares LM .. 2013. Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter. Res Vet Sci. 94 (3): 753–763. [PMC free article] [PubMed] [Google Scholar]
Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori Si, Sakai-Tagawa Y, Iwatsuki-Horimoto K, et al. . 2020. Transmission of SARS-CoV-2 in domestic cats. N Engl J Med. 383 (6): 592–594. [PubMed] [Google Scholar]
Hartmann K, Ritz S .. 2008. Treatment of cats with feline infectious peritonitis. Vet Immunol Immunopathol. 123 (1-2): 172–175. [PMC free article] [PubMed] [Google Scholar]
Hosie MJ, Hartmann K, Hofmann-Lehmann R, Addie DD, Truyen U, Egberink H, Tasker S, Frymus T, Pennisi MG, Möstl K, et al. . 2020. SARS-Coronavirus (CoV) -2 and cats. European Advisory Board on Cat Diseases (ABCD) http://www.abcdcatsvets.org/sars-coronavirus-2-and-cats/. [Google Scholar]
Hsieh LE, Lin CN, Su BL, Jan TR, Chen CM, Wang CH, Lin DS, Lin CT, Chueh LL .. 2010. Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res. 88 (1): 25-30. [PMC free article] [PubMed] [Google Scholar]
Hugo TB, Heading KL .. 2015. Prolonged survival of a cat diagnosed with feline infectious peritonitis by immunohistochemistry. Can Vet J. 56 (1): 53–58. [PMC free article] [PubMed] [Google Scholar]
Ishida T, Shibanai A, Tanaka S, Uchida K, Mochizuki M .. 2004. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J Feline Med Surg. 6 (2): 107–109. [PMC free article] [PubMed] [Google Scholar]
Izes AM, Kimble B, Norris JM, Govendir M .. 2020. a. In vitro hepatic metabolism of mefloquine using microsomes from cats, dogs and the common brush-tailed possum. PLoS One. 15 (4): e0230975. [PMC free article] [PubMed] [Google Scholar]
Izes AM, Kimble B, Govendir M .. 2019. Intrinsic clearance rate of O-desmethyltramadol (M1) by glucuronide conjugation and phase I metabolism by feline, canine and common brush-tailed possum microsomes. Xenobiotica. 50 (7): 776–77. [PubMed] [Google Scholar]
Izes AM, Kimble B, Norris JM, Govendir M .. 2020. b. Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats. PLoS One. 15 (8): e0236754. [PMC free article] [PubMed] [Google Scholar]
Kameshima S, Kimura Y, Doki T, Takano T, Park CH, Itoh N .. 2020. Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis. J Vet Med Sci. 82 (10): 0049-1492. [PMC free article] [PubMed] [Google Scholar]
Kennedy MA. 2020. Feline infectious peritonitis: update on pathogenesis, diagnostics, and treatment. Vet Clin North Am Small Anim Pract. 50 (5): 1001–1011. doi: 10.1016 / j.cvsm.2020.05.002. [PubMed] [CrossRef] [Google Scholar]
Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC .. 2016. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 12 (3): e1005531. [PMC free article] [PubMed] [Google Scholar]
Kim Y, Mandadapu SR, Groutas WC, Chang KO .. 2013. Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. Antiviral Res. 97 (2): 161-168. [PMC free article] [PubMed] [Google Scholar]
Kim Y, Shivanna V, Narayanan S, Prior AM, Weerasekara S, Hua DH, Kankanamalage ACG, Groutas WC, Chang KO .. 2015. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J Virol. 89 (9): 4942–4950. [PMC free article] [PubMed] [Google Scholar]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR .. 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 55 (3): 105924. [PMC free article] [PubMed] [Google Scholar]
Legendre AM, Bartges JW .. 2009. Effect of polyprenyl immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg. 11 (8): 624–626. [PMC free article] [PubMed] [Google Scholar]
Legendre AM, Kuritz T, Galyon G, Baylor VM, Heidel RE .. 2017. Polyprenyl immunostimulant treatment of cats with presumptive non-effusive feline infectious peritonitis in a field study. Front Vet Sci. 4 (Article 7): 7. [PMC free article] [PubMed] [Google Scholar]
McDonagh P, Sheehy PA, Norris JM .. 2014. Identification and characterization of small molecule inhibitors of feline coronavirus replication. Vet Microbiol. 174 (3-4): 438–447. [PMC free article] [PubMed] [Google Scholar]
Mochizuki M, Nakatani H, Yoshida M .. 1994. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet Microbiol. 39 (1-2): 145–152. [PMC free article] [PubMed] [Google Scholar]
Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, Liepnieks M, Pedersen NC .. 2018. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies . Vet Microbiol. 219: 226–233. [PMC free article] [PubMed] [Google Scholar]
Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO .. 2018. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg. 20 (4): 378–392. [PMC free article] [PubMed] [Google Scholar]
Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H .. 2019. Efficacy and safety of the nucleoside analog GS-441524 for the treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 21 (4): 271–281. [PMC free article] [PubMed] [Google Scholar]
Pedersen NC. 2009. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg. 11 (4): 225–258. [PMC free article] [PubMed] [Google Scholar]
Pedersen NC. 2014. a. An update on feline infectious peritonitis: virology and immunopathogenesis. Vet J. 201 (2): 123–132. [PMC free article] [PubMed] [Google Scholar]
Pedersen NC. 2014. b. An update on feline infectious peritonitis: diagnostics and therapeutics. Vet J. 201 (2): 133–141. [PMC free article] [PubMed] [Google Scholar]
Pedersen NC. 2019. a. Fifty years' fascination with FIP culminates in a promising new antiviral. J Feline Med Surg. 21(4):269–270. [PubMed] [Google Scholar]
Pesteanu-Somogyi LD, Radzai C, Pressler BM .. 2006. Prevalence of feline infectious peritonitis in specific cat breeds. J Feline Med Surg. 8 (1): 1–5. [PMC free article] [PubMed] [Google Scholar]
Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, et al. . 2011. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7 (10): e1002331. [PMC free article] [PubMed] [Google Scholar]
Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S, et al. . 2020. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV – infected mice. Sci. Transl. Med. 12 (557): eabc5332. [PMC free article] [PubMed] [Google Scholar]
Ritz S, Egberink H, Hartmann K .. 2007. Effect of feline interferon ‐ omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 21 (6): 1193–1197. [PMC free article] [PubMed] [Google Scholar]
Rohrbach BW, Legendre AM, Baldwin CA, Lein DH, Reed WM, Wilson RB .. 2001. Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals. J Am Vet Med Assoc. 218 (7): 1111–1115. [PubMed] [Google Scholar]
Sailleau C, Dumarest M, Vanhomwegen J, Delaplace M, Caro V, Kwasiborski A, Hourdel V, Chevaillier P, Barbarino A, Comtet L, et al. . 2020. First detection and genome sequencing of SARS ‐ CoV ‐ 2 in an infected cat in France. Transbound Emerg Dis. doi: 10.1111 / tbed.13659 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, et al. . 2020. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2. Science. 368 (6494): 1016–1020. [PMC free article] [PubMed] [Google Scholar]
Sit THC, Brackman CJ, Ip SM, Tam KWS, Law PYT, To EMW, Yu VYT, Sims LD, Tsang DNC, Chu DKW, et al. . 2020. Infection of dogs with SARS-CoV-2. Nature. 586 (7831): 776–778. 10.1038 / s41586-020-2334-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Takano T, Akiyama M, Doki T, Hohdatsu T .. 2019. Antiviral activity of itraconazole against type I feline coronavirus infection. Vet Res. 50 (1): 5. [PMC free article] [PubMed] [Google Scholar]
Takano T, Endoh M, Fukatsu H, Sakurada H, Doki T, Hohdatsu T .. 2017. The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection. Antiviral Res. 145: 96–102. [PMC free article] [PubMed] [Google Scholar]
Takano T, Katoh Y, Doki T, Hohdatsu T .. 2013. Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo. Antiviral Res. 99 (2): 100-107. [PMC free article] [PubMed] [Google Scholar]
Takano T, Satoh K, Doki T, Tanabe T, Hohdatsu T .. 2020. Antiviral effects of hydroxychloroquine and type i interferon on in vitro fatal feline coronavirus infection. Viruses. 12 (5): 576. [PMC free article] [PubMed] [Google Scholar]
Tanaka Y, Sato Y, Osawa S, Inoue M, Tanaka S, Sasaki T .. 2012. Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet Res. 43 (1): 41. [PMC free article] [PubMed] [Google Scholar]
Tanaka Y, Sato Y, Sasaki T .. 2013. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 5 (5): 1250–1260. [PMC free article] [PubMed] [Google Scholar]
Tanaka Y, Sato Y, Takahashi D, Matsumoto H, Sasaki T .. 2015. Treatment of a case of feline infectious peritonitis with cyclosporin A. Vet Rec Case Rep. 3 (1): e000134. [Google Scholar]
Tasker S. 2018. Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests. J Feline Med Surg. 20 (3): 228–243. [PubMed] [Google Scholar]
Theerawatanasirikul S, Kuo CJ, Phetcharat N, Lekcharoensuk P .. 2020. In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus. Vet Res. 174: 104697. [PMC free article] [PubMed] [Google Scholar]
Tsai HY, Chueh LL, Lin CN, Su BL .. 2011. Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan. J Feline Med Surg. 13 (2): 74–80. [PMC free article] [PubMed] [Google Scholar]
Wang L, Mitchell PK, Calle PP, Bartlett SL, McAloose D, Killian ML, Yuan F, Fang Y, Goodman LB, Fredrickson R, et al. . 2020. Complete genome sequence of SARS-CoV-2 in a tiger from a US zoological collection. Microbiol Resour Announc. 9 (22): e00468-20. [PMC free article] [PubMed] [Google Scholar]
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al. . 2020. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial. Lancet. 395 (10236): 1569–1578. [PMC free article] [PubMed] [Google Scholar]
Watari T, Kaneshima T, Tsujimoto H, Ono K, Hasegawa A .. 1998. Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats. J Vet Med Sci. 60 (5): 657–659. [PubMed] [Google Scholar]
Weiss R, Cox N, Martinez M .. 1993. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res Vet Sci. 55 (2): 162–172. [PMC free article] [PubMed] [Google Scholar]
Weiss R, Cox N, Oostrom-Ram T .. 1990. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res. 51 (5): 726–733. [PubMed] [Google Scholar]
Weiss RC, Toivio-Kinnucan M .. 1988. Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon. Am J Vet Res. 49 (8): 1329–1335. Aug [PubMed] [Google Scholar]
Woo PCY, Lau SKP, Lam CSF, Lau CCY, Tsang AKL, Lau JHN, Bai R, Teng JLL, Tsang CCC, Wang M, et al. . 2012. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 86 (7): 3995–4008. [PMC free article] [PubMed] [Google Scholar]
Woo PCY, Lau SKP, Yip CCY, Huang Y, Tsoi HW, Chan KH, Yuen KY .. 2006. Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1. J Virol. 80 (14): 7136–7145. [PMC free article] [PubMed] [Google Scholar]
Worthing KA, Wigney DI, Dhand NK, Fawcett A, McDonagh P, Malik R, Norris JM .. 2012. Risk factors for feline infectious peritonitis in Australian cats. J Feline Med Surg. 14 (6): 405–412. [PubMed] [Google Scholar]
Yu J, Kimble B, Norris JM, Govendir M .. 2020. Pharmacokinetic profile of oral administration of mefloquine to clinically normal cats: a preiminary in-vivo study of a potential treatment for feline infectious peritonitis (FIP). Animals. 10 (6): 1000. [PMC free article] [PubMed] [Google Scholar]
You can find the whole article on the server biorxiv.org; 13.11.2020.
Abstract
The unprecedented coronavirus disease pandemic of 2019 (COVID-19) caused by the second severe acute respiratory syndrome virus (SARS-CoV-2) poses a serious threat to public health worldwide. There is an urgent need to develop effective therapies against SARS-CoV-2. We evaluated the antiviral activity of the original remdesivirus nucleotide analog, GS441524, which targets the enzyme RNA-dependent RNA polymerase, and the protease inhibitor GC376, which targets the protease SARS-CoV 2 in infected mice. Our results showed that GS441524 effectively blocked SARS-CoV-2 proliferation (multiplication) in the upper and lower airways with combined intranasal (in) and intramuscular (im) therapy. The efficacy of the high dose of GC376 (im or in and im) was weaker than GS441524. However, it is noteworthy that the combined administration of GS441524 together with GC376 at low doses could effectively protect mice from SARS-CoV-2 infection during in or in and their treatment. We further found that the pharmacokinetic properties of GS441524 were superior to GC376, and the combined application of GC376 and GS441524 had a synergistic effect. Our findings will be used to further evaluate the combined application of GC376 and GS441524 in future clinical trials.
Feline coronavirus (FCoV) can cause a fatal disease - feline infectious peritonitis. Cats that permanently shed this virus are the most important sources of infection. The role of the host in faecal excretion of FCoV is unknown. The aim of this study was to identify gene markers and test their association with FCoV secretion patterns. Fecal samples were taken from 57 cats of 12 breeds at baseline and then at 2, 4 and 12 months. Variations from persistent and / or high intensity excretion to no excretion were observed. Thirteen immune-related genes were selected as functional and positional / functional candidates. Positional candidates were selected in the candidate area detected by GWAS analysis. Tens to hundreds of single nucleotide polymorphisms (SNPs) per gene have been identified by next generation sequencing. Associations with different phenotypes were evaluated by chi-square tests and Fisher's exact tests. SNP of one functional and one position candidate (NCR1 and SLX4IP ) and haplotypes of four genes ( SNX5 , NCR2 , SLX4IP , NCR1 ) were associated with FCoV excretion at p cor<0.01. Highly significant associations have been observed in extreme phenotypes (persistent / high-intensity secretors and non-excretors), suggesting that there are two major phenotypes associated with different genotypes - highly susceptible cats that persistently excrete high levels of viral particles, and coronavirus-resistant cats. do not exclude.
Keywords: feline enteric coronavirus, faecal excretion patterns, polymerase chain reaction, genetic susceptibility, candidate immune-related genes, association study
MOSCOW (Reuters) - Russian drugmaker Pharmasyntez has asked the Kremlin to allow it to produce a generic version of the US drug COVID-19 remdesivir, which is used to treat US President Donald Trump, despite not having a patent, the company director said on Monday.
Remdesivir is not available in Russia, said Pharmasyntez CEO Vikram Punia, but the generic version cannot be produced and distributed without the consent of the patent holder, the American company Gilead Sciences GILD.O.
In July, Pharmasyntez asked the American company for approval in the form of a voluntary license, but did not receive any response, Punia said.
The Siberian drugmaker is now asking the Kremlin to activate a compulsory licensing process based on national security concerns, giving it the right to produce a generic Remdeform without the consent of Gilead.
"This drug could save many lives. The longer this drug is unavailable, the more people we will lose," Punia said.
The law has never been applied to a pharmaceutical product in Russia, Punia said after the daily Vedomosti reported on a letter from his company to the Kremlin on Monday.
It was not possible to contact Gilead on Monday outside normal business hours to comment on the situation. It has already granted voluntary licenses to manufacturers in 127 countries, mainly in low-income countries or in countries that have other significant barriers to accessing healthcare.
Russia recorded a record high 18,665 new cases of coronavirus on Sunday, bringing the total number since the start of the pandemic to 1,655,038.
Remdesivir was granted emergency use by the US Food and Drug Administration in May after government-initiated tests have shown that it shortens hospital stays for patients with COVID-19. He was one of the drugs Trump received during his treatment for this disease.
The FDA officially approved the drug this month, despite the recent results of a study sponsored by the World Health Organization, which showed that remdesivir did not improve patients.
According to a record in the registry, Pharmasyntez has completed clinical trials of a generic drug on 300 patients with COVID-19 in 23 Russian hospitals.
Punia said the company could sell its drug at a significantly lower price of around 540$ for 6 vials. Five days of remedivirus treatment from Gilead, sold under the Veklury brand, was priced at 3120$.
In animal studies, Chinese researchers found that a metabolite of the antiviral drug Remdesivir called GS-441524 could help inhibit the SARS-CoV-2 virus, which causes COVID-19.
The virus has infected more than 46.85 million people worldwide and already has more than 1.2 million lives killed. To date, there is no effective antiviral drug available to treat this infection, and there are no vaccines available to block the infection.
Remdesivir, a broad-spectrum antiviral drug developed by the biopharmaceutical company Gilead Sciences, has demonstrated initial success against this viral infection. This medicine is approved or authorized for emergency use in the treatment of COVID - 19 in 50 countries.
A new study entitled "Remdesivir Metabolite GS-441524 Efficient Inhibits SARS-CoV-2 Infection in Mouse Model" was released online in advance on the server bioRxiv before going through the review process.
Proposed metabolic pathway of remdesivir and chemical structures of metabolites
Basic facts
The COVID-19 pandemic is currently raging without an effective antiviral drug. In most cases, SARS CoV-2 only leads to mild respiratory symptoms, but in some individuals it can lead to acute severe respiratory syndrome (ARDS) and be fatal.
Remdesivir is currently the only COVID-19 treatment approved by the US Food and Drug Administration (FDA). Remdesivir is an inhibitor of RNA-dependent RNA polymerase (RdRP). The recent publication of the results of the World Health Organization's (WHO) Solidarity Trial questioned the effectiveness of Remdesivir against SARS CoV-2. The results of the study questioned its effectiveness in shortening hospital stays and reducing the risk of death in patients with COVID-19.
Pharmacokinetics of Remdesivir
Studies have shown that remdesivir is metabolised after intravenous administration to active metabolites called GS-704277, GS-441524 (original nucleoside) and GS-443902. The most important and important metabolite is GS-441524. GS-441524 has a long half-life of about 27 hours, while Remdesivir in its unaltered form has a half-life in the body of about 1 hour. GS-441524 also has greater bioavailability compared to unchanged Remdesivir. The authors write that the implications of these differences in the pharmacokinetics of unchanged remdesivir and its major metabolite are not clearly understood.
Efficacy of remdesivir and its metabolite
Laboratory studies have shown that GS-441524 is less active against Ebola virus, hepatitis C virus and respiratory syncytial virus (RSV) compared to unchanged Remdesivirus. GS441524 is converted to monophosphate in the body. This is the most important step in activating the drug. Remdesivir, in its unchanged form, bypasses this step and also has a better ability to penetrate the cell. However, studies have shown that GS441524 has potent activity against human coronaviruses (CoVs), including SARS CoVs 1 and 2, Middle East coronaviruses (MERS-CoVs), etc. It is also effective in inhibiting feline coronavirus infectious peritonitis (FIP) (FCoV). GS-441524 has shown success in the treatment of FIP 96%, the researchers explain.
Purpose of the study
The purpose of the study was to compare the efficacy of GS-441524 and Remdesivir against SARS-CoV-2 in vitro.
The efficacy of Remdesivir and GS-441524 was observed against SARS CoV-2 and mouse hepatitis virus (MHV) in mouse models. Drug pharmacokinetic parameters were also tested in animal models and cell cultures. Vero E6 cells (African green monkey kidney cells), calu-3 (human lung adenocarcinoma cell) and caco-2 cells (colorectal adenocarcinoma) were used for this study. They also used genetically modified or AAV-hACE2 transduced mice and mice with mouse hepatitis virus (MHV).
The overall results showed that the original nucleotide of Remdesivir, GS-441524, was able to inhibit SARS-CoV-2 replication in Vero E6 and other cells. The results of the study were:
GS-441524 was found to have good plasma distribution in animal bodies after administration
GS-441524 had a long half-life in the bodies of mice - almost 4.8 hours
GS-441524 was found to have better plasma stability compared to Remdesivir.
GS-441524 has been found to be effective in reducing viral load in affected organs in MHV transduced mice. Organ toxicity also decreased with drug use.
The authors stated that these results were "consistent with previously published studies that the relative efficacy of GS-441524 and remdesivir depends on the cell type."
GS-441524 did not cause toxicity to the treated cells, suggesting "its good safety profile," the researchers wrote.
"GS-441524 treatment was able to significantly suppress virus replication in the lungs by more than 99.9 percent," the researchers wrote.
Conclusions and implications
The study researchers concluded that GS-441524 was the major and major metabolite of remdesivir in plasma. The effects of remdesivir on COVID-19 may be due in part to this metabolite. The team wrote that their study showed that GS-441524 could be "a promising and inexpensive drug candidate in the treatment of COVID-19 and future CoV diseases."
* Important note
BioRxiv publishes preliminary scientific reports that have not been peer-reviewed and should therefore not be considered validated as relevant to clinical practice / health-related behavior, nor should they be treated as official information.
This is the first report of successful treatment of a case of non-fusive FIP uveitis using the oral form of the adenosine analog and feline interferon omega, and alpha-1 acid glycoprotein (AGP) as an indicator of recovery. A 2-year-old neutered Norwegian Forest Cat has been affected by uveitis, keratic clots, mesenteric lymphadenopathy and weight loss. He was hypergammaglobulinemic and had non-regenerative anemia. Feline coronavirus (FCoV) RNA was detected by thin-needle aspiration of mesenteric lymph nodes using polymerase chain reaction reverse transcription (RT-PCR) - non-fusive FIP was diagnosed. Prednisolone acetate eye drops were administered three times daily for 2 weeks. Treatment with an oral form of an adenosine analogue (Mutian) was started. After 50 days of Mutian treatment, the cat gained more than one kilogram, the globulin level decreased from 77 to 51 g / l, and the hematocrit increased from 22 to 35%; uveitis subsided and vision improved. Serum AGP levels decreased from 3100 to 400 μg / ml (within normal limits). Symmetric dimethylarginine (SDMA) was above normal at 28 μg / dl, declining to 14 μg / dl at the end of treatment; It is not known whether the increase in SDMA was due to FIP lesions in the kidney or Mutian. After cessation of Mutian treatment, low doses of the oral form of recombinant feline interferon omega were started - recovery of the cat continued.
Feline coronavirus (FCoV) is a highly infectious enteric virus that causes subclinical infection or diarrhea in most infected cats. [1], but in about 10% it causes potentially fatal immune-mediated monocyte-associated granulomatous vasculitis [2], known as feline infectious peritonitis (FIP). FCoV is an alpha coronavirus with positive polarity, a member of the Coronaviridae family of the Nidovirales family. [3].
Although treatment of FIP with an injectable nucleoside analog has been described in the past [4] and cure of enteric FCoV infection by oral form of adenosine analog (Mutian, Nantong Biotechnology, China) [5], this is the first reported case of recovery of a cat with a systemic FCoV infection - i.e. FIP - using Mutian.
2. Case study
Skywise was a 2-year-old neutered male Norwegian Forest Cat from a household with five cats; he developed uveitis in the remaining eye (in the right, he lost his left eye as a kitten) and occasional diarrhea. Its iris was unnaturally colored and grainy fat precipitates were visible (Figure 1a).
Figure 1 Cat's eye before (a) and (b) after treatment with Mutian and topical steroids. The cat had uveitis and keratic clots (a). Right (b): the same eye after 7 days of systemic prednisolone, 2 weeks of topical prednisolone and 7 weeks of Mutian treatment, showing almost complete resolution of uveitis.
His medical history included bringing two 11-month-old Norwegian Forest Cats (Link and Zelda) into the home three months ago and the onset of uveitis five days after revaccination (Leucofeligen, Virbac, France). Skywise was tested for FCoV antibodies and was found to have a very high titer above 10,240 (Idexx Laboratories, Wetherby, UK) three weeks before presentation due to the contact cat (Paddy) being persistently pyrexic and malaise. . Paddy was negative for FeLV p27 antigens and FIV antibodies (Idexx Laboratories, Wetherby, UK), but his anti-FCoV antibody titer was found to be very high (Table 1), so all other domestic cats were tested for FCoV antibodies to decided whether they should be isolated from Paddy, but since they were also found to have high FCoV antibody titers (Table 1), segregation was not necessary.
Day −29
Day −19
Day 7
Day 41
Skywise
2 years - Norwegian Forest Cat (NFC) FIP
> 10,240
CT 30
Neg
Paddy
2 years - NFC, persistent pyrexia, lethargy
> 10,240
CT 18
Neg
Oliver
8 years old - Domestic shorthair cat
> 10,240
CT 20
Neg
Link
1 year - NFC
> 10,240
CT 20
Neg
Zelda
1 year - NFC
640
Neg
Neg
Table 1
Feline coronavirus (FCoV) antibody titer and qRT-PCR C resultsT.
CT - Cycle threshold for FCoV qRT-PCR performed on a stool sample. The days are relative to the first presumed diagnosis of feline infectious peritonitis (FIP) at Skywise on day 0 (April 18, 2020); ie. its FCoV antibody titer was tested 19 days before the diagnosis of FIP. Mutian treatment was started for Skywise on day 6 and for other FCoV infected cats on day 18 for 5 days.
At presentation, the patient's body weight was 2.89 kg (Figure 2) and the fitness score was 2/9. Ultrasound confirmed the absence of abdominal or thoracic effusion, but mesenteric lymphadenopathy was present. Mesenteric lymph node (MLN) aspirate was collected by ultrasound-guided thin-needle aspiration biopsy (FNA) and tested for FCoV reverse transcription polymerase chain reaction (qRT-PCR) (Idexx Laboratories, Wetherby, UK). The assay was positive for the M1058L mutation and negative for the S1060A mutation [6].
Figure 2 Weight before, during and after FIP recovery and timeline. The weight of the cat is shown in the graph above: Day 0 represents the day of presentation with uveitis at the clinic. Revaccination was performed 5 days before the onset of uveitis, but the cat's weight was not recorded before that day, so it is not known whether she lost weight before revaccination or whether there was weight loss after revaccination; ie. whether the FIP was pre-vaccinated or whether the FIP was due to revaccination itself. The cat lost 30 g of weight during systemic treatment with prednisolone (days 0 to 6), then only topical steroids were administered. Mutian treatment was between days 6 and 56; after starting Mutian treatment, the cat's weight increased rapidly and weight gain continued even after Mutian was replaced by feline interferon omega, until the cat's weight reached about 4.35 kg.
The blood results are shown in Table 2. Hematology revealed mild to moderate non-regenerative anemia with hematocrit (HCT) 22%, lymphocyte count 2.07 × 109/ la by eosinopenia below the detection level (reported as 0.0 × 109/ l). Biochemical analysis of the blood showed hyperglobulinemia (77.2 g / l) and an albumin to globulin (A: G) ratio of 0.31. Bilirubin was 11 micromoles per liter (μmol / l) (0.64 mg / dl). Alpha-1 acid glygoprotein (AGP) was increased to 3100 μg / ml (Idexx Laboratories, Wetherby, UK) (normal level is ≤ 500 μg / ml [7]).
AGP
TP
Alb
Glob
A: G
Bilirubin
Hct
Lymphocytes
ALT
AP
GGT
SDMA
Creat
Urea
Ref. range
<500 μg / mL
57-89 g / L
22-40 g / L
28-51 g / L
> 0.8 *
0–15 μmol / L
30–52%
0.92–6.88 × 109
12-130 U / L
14-111 U / L
0–4 U / L
0-14 μg / dL
71–212 μmol / L
5.7–12.9 mmol / L
Day 0
ND
111
20
91
0.22
11
25.7
0.95
64
ND
ND
ND
ND
ND
Day 2
3100
103
24
77
0.31
ND
22.0
2.07
ND
ND
ND
ND
ND
ND
Day 18
700
83
26
57
0.46
6
34.4
3.61
27
32
0
ND
88
9.6
Day 41
400
80
29
51
0.57
5
35.1
3.85
67
40
0
28
93
8.3
Day 62
400
78
30
48
0.60
5
35.2
2.64
61
40
0
19
106
6.5
Day 90
300
78
31
47
0.70
6
40.0
4.15
81
40
0
14
113
10.0
Day 153
400
67
34
33
1.03
1
35.2
4.49
81
46
2
ND **
98
7.8
Table 2
Laboratory data related to FIP treatment monitoring.
* A: G above 0.8 has a strong negative predictive value for FIP [8]. ** SDMA was not repeated because urine analysis was normal. AGP - alpha-1 acid glycoprotein; TP - total protein; Alb - albumin; Glob - globulin; A: G - ratio of albumin to globulin; Hct - hematocrit; ALT - alanine aminotransferase; AP - alkaline phosphatase; GGT - gamma glutamyltransferase; SDMA - symmetric dimethylarginine; Creat - creatinine; ND = not determined.
Only parameters that have been monitored repeatedly are shown in this table; others for which few (or no) results were available (eg aspartate aminotransferase) or which were not relevant to the procedure in this case are omitted. FCoV antibody titers and faecal FCoV qRT-PCR results are shown in Table 1. Day 0 is the day of FIP diagnosis in the first cat; Mutian was administered between days 6 and 56, after which the cat was treated with 100,000 units of the oral form of feline interferon omega.
Systemic treatment was initiated with prednisolone 5 mg for uveitis (Table 3). The dose was reduced to 2.5 mg sid, then stopped after 7 days and replaced with topical prednisolone-acetate 1% eye suspension (Pred Forte®, Allergan, Dublin, Ireland) applied every 8 hours for two weeks. On the sixth day after the presentation, treatment with an oral adenosine analogue began (Mutian 200, Nantong Biotechnology, Nantong, China). [5] at a dose of 8 mg / kg every 24 hours in divided doses: this was twice the normal dose, in an effort to ensure penetration into the eyeball. S-adenosyl-L-methionine supplementation was recommended to support the liver during treatment with Mutian. The dose of Mutian was reduced to 6 mg / kg on day 25, but by then the weight of the cat had increased, so the same number of capsules per day was required.
Treatment
Day
Ophthalmoscopic findings
Systemic prednisolone
0
Day of presentation to the primary veterinarian.
1
Eye examined using a standard ophthalmoscope. Cornea unchanged, anterior chamber slightly cloudy, but sedation would be required for a detailed examination. Cat blind and stressed.
2
Blood samples and aspirates of mesenteric lymph nodes with a thin needle taken under sedation.
Topically prednisolone acetate 1% tid
4
Keratin (protein) precipitated on the lens, which partially covers the fundus. Pupillary light reflex present but reduced.
Mutian 8mg / kg for 19 days, then 6mg / kg
6
The cat's caregiver said he thought the cat could see.
17
The cat's caregiver said the cat was chasing a bird.
18
Uveitis recedes, anterior chamber clear. Ceramic precipitates as before.
41
Uveitis has largely subsided, keratic precipitates still present. The fundus was visible, the chorioretinitis had subsided, and the cat's high temperament made detailed examination impossible. Excellent visual sensitivity.
Table 3 Timeline of treatment and resolution of uveitis.
To evaluate the susceptibility of the FCoV strain to the antiviral drug used, faecal samples were subjected to an FCoV qRT-PCR test (Veterinary Diagnostic Services, University of Glasgow, Scotland) [5]; the result was weakly positive in the threshold cycle (CT) 30, then negative, indicating that the virus was sensitive to the antiviral (Table 1). The faeces of three of the other four domestic cats were also positive for FCoV RNA (Table 1).
After starting Mutian treatment, the cat's weight increased rapidly, while it decreased by 30 g (2.89-2.86 kg) during prednisolone treatment (Figure 2). After 40 days of Mutian, the cat gained one kilogram (Figure 2). The dose of Mutian was adjusted during treatment in accordance with weight gain.
Blood tests were repeated on day 13 of Mutian treatment (18 days after diagnosis) (Table 2). Most importantly, the anemia reversed, HCT increased from 22.0 to 34.4%, and bilirubin decreased from 11 to 6 μmol / L. Globulin decreased to 57 g / l and albumin increased by 2 g / l, so the albumin: globulin ratio increased from 0.31 to 0.46, which was still a small but still improvement (Figure 3). Clinical examination revealed that iris color had returned to normal (Figure 1, Table 3) and vision improved; the caregiver reported an increase in activity - playing with other cats - and that the cat was trying to catch a bird. His droppings regained their normal consistency and frequency.
Figure 3 Timeline of treatment in relation to globulin albumin levels, showing a decrease in globulin (and thus total protein) levels, an increase in albumin and an albumin to globulin ratio. Improvement in these parameters continued after discontinuation of Mutian and feline interferon omega therapy.
The dose of Mutian was reduced to 6 mg / kg on day 20 and treatment with Mutian was stopped after 7 weeks for two reasons: AGP levels returned to normal (400 μg / ml - normal is <500 μg / ml), and because SDMA rose to 28 μg / dl (reference range is below 14 μg / dl). Recombinant feline interferon omega (rFeIFN-ω; Virbagen Omega, Virbac, France) started at 100,000 units every 24 hours orally. SDMA decreased to 19 μg / dl on day 62 (one week after the end of Mutian treatment) and to 14 μg / dl on day 90, which was 35 days after the end of Mutian treatment (Table 2). Urine analysis performed at days 62, 90, and 153 revealed no abnormalities, and the specific gravity was 1,050, 1,055, and 1,050, respectively. Weight gain continued after stopping Mutian treatment and using feline interferon omega (Figure 1), albeit at a slower rate (average 9g / day instead of 23g / day).
Cohabiting cats were successfully treated with Mutian at a dose of 4 mg / kg for five days to prevent coronavirus secretion and thus recurrent recovery of the recovered cat; the faeces of all five cats were confirmed as negative by RT-PCR (Table 1).
3. Discussion
The successful treatment of FIP with antiviral drugs was first published by Dr. Pedersen [4,9]. Cat owners can obtain various anti-FCoV drugs, including Mutian, an oral form of adenosine analog, over the Internet. However, such medicines are not licensed for veterinary use, which puts treating veterinarians in a dilemma: they cannot prescribe or supply such treatment, but they can help clients who choose to take these medicines by providing diagnostic and routine supportive care. It is particularly useful to make an accurate diagnosis that will prevent the treatment of about 40% cats that would otherwise be misdiagnosed (data not shown). Our view is that it would be more appropriate for cat owners to use such drugs under proper veterinary supervision, even if these products are unlicensed. The purpose of this case study is to report what has worked for us in monitoring a case of non-fusible FIP treated with Mutian followed by feline interferon.
Diagnosis of non-fusive FIP is challenging because the symptoms are diverse and the list of differential diagnoses is often lengthy. Dunbar et al. 2019 [10], reported that detection of FCoV RNA from Mesenteric Lymph Node (MLN) FNA (Fine Needle Aspiration) is 96% specific for FIP diagnostics. Unfortunately, the lab initially erroneously performed the FCoV RT-PCR test on a blood sample from day 2, instead of the MLN FNA as required - and the test turned negative. FCoV RT-PCR on blood samples is not useful in the diagnosis of FIP because most cats with FIP are not viremic at the time of clinical manifestations. [11] and also because about 5% cats do not test positive for FIP [12,13] because FCoV-infected cats undergo transient viremia [12,13,14,15]. FCoV RNA was found in feline MLN FNA and revealed to be positive for the M1058L mutation, which was further evidence to support the diagnosis of FIP [6,11]; although substitution with methionine for leucine at position 1058 in the FCoV spike protein was found in 89% tissue samples from 14 cats without FIP, suggesting that the mutation indicates systemic spread of FCoV from the gut rather than a virus with the potential to cause FIP [16].
Despite laboratory delays in confirming the diagnosis of FIP, we initiated Mutian treatment based on history, clinical signs, blood scores, and elevated AGP, which had previously been shown to be very specific for distinguishing FIP from other diseases with similar manifestations. [17]. There was an urgency to start treatment because the FIP male staging score was 6, indicating death within two weeks. [18]. The HCT of the cat decreased rapidly (from 25.7 to 22% in two days), which proved to be an indicator of imminent near death: Tsai et al., (2011) [18] found that HCT levels drop dramatically 2 weeks before death and bilirubin increases one week before death.
The history of the cat was typical of many cases of FIP: two new 11-month-old purebred cats were introduced into the household, which were probably the source of a recent coronavirus infection; the cat was vaccinated five days before the onset of uveitis. Introducing new cats and vaccinations are stressful for cats - it is known that stress causes FIP in cats infected with FCoV [19] and Riemer et al., (2016) [20] found that vaccination was a suspected stress factor in 6.9 % cases of FIP. Unfortunately, the weight of the cat between the introduction of new cats and vaccination was not recorded, so it is not known whether he lost weight during revaccination (ie was subclinically ill with FIP) or whether weight loss started later. This case nevertheless illustrates that vaccination of FCoV-infected cats may pose a risk to the development of FIP, and that optimal vaccination should be performed after the cat has stopped shedding the virus, which occurs within a few months for most FCoV type 1 infections. [21 ].
Clinical signs of weight loss, appetite, diarrhea and uveitis were also consistent with the diagnosis of non-fusive FIP. FIP is a major cause of uveitis in young cats - ophthalmologists from the North Carolina Veterinary School diagnosed FIP in 19 of 120 cats (15.8%) with uveitis [22]. Uveitis was reported in 17 of 59 (29%) cats with non-fusive FIP [23].
Although treatment with an injectable nucleoside analogue has been documented previously in the treatment of FIP [4], to our knowledge, oral treatment of FIP with an adenosine analogue has not been previously reported, although it has been used to treat FCoV infection in asymptomatic or diarrhea cats. [5]. The patient was given twice the normal therapeutic dose of FIP (ie, 8 mg / kg vs. 4 mg / kg) to potentially increase the concentration of the drug in the eye and to rule out any virus that might be present in the brain because only 20% of the absorbed drug passes through the blood-brain barrier (T Xue, personal communication). The response to treatment was rapid, dramatic and extremely positive. Although we tried to reduce the dose of Mutian as soon as possible in the event of possible side effects, in practice the amount of medication did not change significantly because the cat gained weight at the same time. Pedersen et al., (2019) [4] stated that the simplest indicator of response to treatment was weight gain, which was staggering in this case, as the cat gained 1.1 kg during the first 50 days of treatment. In contrast, he lost 30g during the week on prednisolone, before starting treatment with Mutian.
In two studies, cats with FIP treated with corticosteroids had a median survival of 7.5 days [24] and 8 days [25], which is significantly shorter than the 21 - day average reported by Tsai et al., 2011 [18] (although the potential adverse effects of biopsies on survival need to be considered in the two studies and many deaths were due to secondary bacterial infection due to extensive corticosteroid-induced immunosuppression [25]). In addition, prednisolone treatment was previously found to shorten survival in FIP cats that were co-treated with polyprenyl immunostimulant. [23]. Therefore, in our case, systemic corticosteroids were replaced by topical corticosteroids for the treatment of uveitis.
We do not know if it was Mutian, systemic and topical steroids, or a combination of all treatments that affected the overall cure of uveitis. The cat owner reported a partial return of vision on day 6, which was the day Mutian treatment was started, suggesting that steroids were responsible for return vision (Table 3). Legendre et al., (2017) [23] reported progress in 3 of 17 cats with ocular FIP treated with polyprenyl immunostimulant (PI). Their initial symptoms included anterior uveitis (all three cats), clots of ceramic origin (one cat), iris discoloration (one cat) and anisocoria (one cat). In two cats, anterior uveitis significantly improved or resolved after 2 months of PI treatment without corticosteroids. In the third cat, uveitis did not improve; the cat received topical ocular corticosteroids at the same time as PI and the eyes were enucleated [23]. Whether or not Mutian alone can affect the treatment of FIP-associated uveitis without current topical corticosteroids remains to be seen. Systemic corticosteroids appear to have little or no significance in these cases.
No clinical side effects were observed during treatment with Mutian and the biochemical parameters of the liver and kidney were within the reference range, with the exception of plasma symmetric dimethylarginine (SDMA), which increased (Table 2). SDMA is an early indicator of kidney disease [26,27]. There are three possible explanations for increased SDMA: first, it may be due to FIP lesions in the kidneys. Azotemia is more likely in non-effusive than effusive FIP [20], but as far as we know, no study has been conducted to determine whether SDMA is rising in cats with FIP - veterinary pathologists speculate that transient FCoV infection of the kidneys may be the cause of interstitial nephritis observed in many older cats (W Jarrett and S Toth, personal communication ). Second, predisposition to the breed may be a factor - Birm cats have been found to have elevated SDMA levels. [28], but no study has been performed on SDMA levels in Norwegian Forest Cats and in cats, SDMA levels have fallen to normal levels, suggesting that the increased SDMA levels did not appear to be related to his breed. Third, increased SDMA may have been a side effect of Mutian treatment - SDMA decreased within seven days after the end of Mutian treatment and returned to normal within 35 days after the end of Mutian treatment. However, because we did not test it earlier during the disease, we do not know if it was increased before the deployment of Mutian. During treatment, cat creatinine and urea were always within normal limits, although a progressive increase in creatinine was observed (Table 2), which will be closely monitored in the future.
Because the recommended time of administration of GS-441524 was 84 days [4], cat owners using other antivirals have been treating their cats with FIP for the same length of time. The optimal duration of FIP oral Mutian treatment has not been established. However, this case illustrates that treatment can be stopped after a much shorter cycle if laboratory indicators for FIP return to normal. We believe that in our case, complete recovery occurred after 50 days of treatment for the following reasons - uveitis subsided, the cat recovered from anemia, lymphopenia reversed, bilirubin decreased and AGP decreased permanently. Nevertheless, we did not want to leave the cat completely without antiviral coverage, so a low oral dose of rFeIFN-omega was used as described above. [29]. This drug has antiviral and immunomodulatory properties and was an optional treatment for FIP with meloxicam prior to the onset of specific antiviral drugs against FCoV. [30]. The cat continued to gain weight with rFeIFN-omega, although more slowly than before, stabilized at 4.35 kg after 100 days (Figure 2) and hematological parameters continued to improve (Table 2, Figure 3).
FIP relapse did not occur in this - or in other - cases whose treatment we monitored. We attribute our success primarily to assessing the effectiveness of an antiviral agent against the FCoV strain in an infected cat by monitoring the amount of virus excreted in the stool (by qRT-PCR) to ensure that the viral load decreased in response to the antiviral agent; second, preventing FIP-cured re-infection by identifying other sources of viruses in the same household and stopping FCoV shedding by Mutian [5]; third, short-term treatment with a dose that eliminated the virus from the brain; fourth, after treatment with a nucleoside analogue (or protease inhibitor) by initiating a low dose of oral feline interferon until the FCoV antibody titer has decreased - an indicator that no coronavirus remains in the body.
Skywise and his roommates are alive and well 6 months after diagnosis.
4. Conclusions
To our knowledge, this is the first published case of curing a non-fusive FIP cat using an oral adenosine analogue, followed by a recombinant feline interferon, and AGP used as a recovery marker from FIP. To protect the liver and monitor liver enzymes, we recommend taking SAMe with Mutian. SDMA levels in future cases following this FIP treatment protocol require further investigation. We suggest that systemic corticosteroids be contraindicated in the treatment of FIP for non-palliative purposes.
Acknowledgement
We would like to thank the reviewers for their time in thoroughly reviewing our work and for their helpful comments: Table 1 and Table 3 were added thanks to their comments.
Author's contributions
Conceptualization, DDA and JC-R .; methodology, MF, OJ and DDA .; validation, OJ, DDA, JC-R. and MF .; formal analysis, MF and DDA .; investigation, MF and JC-R .; sources, JC-R. and MF .; data management, DDA, JC-R. and MF .; writing - preparation of the original proposal, DDA; writing - reviews and edits, OJ, DDA, JC-R. and MF .; visualization, DDA and JC-R .; supervision, DDA and JC-R .; project administration, JC-R., MF. financing acquisition, JC-R. and DDA All authors have read and agreed to the published version of the manuscript.
Financing
Cat treatment and lab tests were funded by JC-RDDA Thank you subscribers www.catvirus.com for support during this study and we are very grateful to the Angelica Fund donor for the payment of publication fees.
References
Addie DD, Toth S., Murray GD, Jarrett O. The risk of feline infectious peritonitis in cats naturally infected with feline coronavirus. Am. J. Vet. Res. 1995;56: 429–434. [PubMed] [Google Scholar]
Kipar A., May H., Menger S., Weber M., Leukert W., Reinacher M. Morphologic features and development of granulomatous vasculitis in feline infectious peritonitis. Vet. Pathol. 2005;42: 321–330. doi: 10.1354 / vp.42-3-321. [PubMed] [CrossRef] [Google Scholar]
De Groot RJ, Baker SC, Baric R., Enjuanes L., Gorbalenya AE, Holmes KV, Perlman S., Poon L., Rottier PJM, Talbot PJ, et al. Family Coronaviridae. In: Adams MJ, Carstens EB, Lefkowitz EJ, editors. Ninth Report International Committee on Taxonomy of Viruses; King AMQ. Elsevier; Amsterdam, The Netherlands: 2012. pp. 806–828. [Google Scholar]
Pedersen NC, Perron M., Bannasch M., Montgomery E., Murakami E., Liepnieks M., Liu H. Efficacy and safety of the nucleoside analog GS-441524 for the treatment of cats with naturally occurring feline infectious peritonitis. J. Feline Med. Surg. 2019;21: 271–281. doi: 10.1177 / 1098612X19825701. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Duthie S., Eckersall PD, Addie DD, Lawrence CE, Jarrett O. Value of alpha1-acid glycoprotein in the diagnosis of feline infectious peritonitis. Vet. Rec. 1997;141: 299–303. doi: 10.1136 / vr.141.12.299. [PubMed] [CrossRef] [Google Scholar]
Shelly SM, Scarlett-Kranz J., Blue JT Protein electrophoresis on effusions from cats as a diagnostic test for feline infectious peritonitis. J. Am. Anim. Hosp. Assoc. 1988;24: 495–500. [Google Scholar]
Pedersen NC, Kim Y., Liu H., Galasiti KAC, Eckstrand C., Groutas WC, Bannasch M., Meadows JM, Chang KO Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 2018;20: 378–392. doi: 10.1177 / 1098612X17729626. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Dunbar D., Kwok W., Graham E., Armitage A., Irvine R., Johnston P., McDonald M., Montgomery D., Nicolson L., Robertson E., et al. Diagnosis of non-effusive feline infectious peritonitis by reverse transcriptase quantitative polymerase chain reaction from mesenteric lymph node fine needle aspirates. J. Feline Med. Surg. 2019;21: 910–921. doi: 10.1177 / 1098612X18809165. [PubMed] [CrossRef] [Google Scholar]
Felten S., Leutenegger CM, Balzer HJ, Pantchev N., Matiasek K., Wess G., Egberink H., Hartmann K. Sensitivity and specificity of a real-time reverse transcriptase polymerase chain reaction detecting feline coronavirus mutations in effusion and serum / plasma of cats to diagnose feline infectious peritonitis. BMC Vet. Res. 2017;13: 228. doi: 10.1186 / s12917-017-1147-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Fish EJ, Diniz PPV, Juan YC, Bossong F., Collisson EW, Drechsler Y., Kaltenboeck B. Cross-sectional quantitative RT-PCR study of feline coronavirus viremia and replication in peripheral blood of healthy shelter cats in Southern California. J. Feline Med. Surg. 2018;20: 295–301. doi: 10.1177 / 1098612X17705227. [PubMed] [CrossRef] [Google Scholar]
Simons FA, Vennema H., Rofina JE, Pol JM, Horzinek MC, Rottier PJ, Egberink HF A mRNA PCR for the diagnosis of feline infectious peritonitis. J. Virol. Methods. 2005;124: 111–116. doi: 10.1016 / j.jviromet.2004.11.012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Herrewegh AAPM, de Groot RJ, Cepica A., Egberink HF, Horzinek MC, Rottier PJM Detection of feline coronavirus RNA in feces, tissue, and body fluids of naturally infected cats by reverse transcriptase PCR. J. Clin. Microbiol. 1995;33: 684–689. doi: 10.1128 / JCM.33.3.684-689.1995. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Tasker S. Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests. J. Feline Med. Surg. 2018;20: 228–243. doi: 10.1177 / 1098612X18758592. [PubMed] [CrossRef] [Google Scholar]
Porter E., Tasker S., Day MJ, Harley R., Kipar A., Siddell SG, Helps CR Amino acid changes in the spike protein of feline coronavirus correlate with systemic spread of virus from the intestine and not with feline infectious peritonitis. Vet. Res. 2014;45: 49. doi: 10.1186 / 1297-9716-45-49. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Giori L., Giordano A., Giudice C., Grieco V., Paltrinieri S. Performances of different diagnostic tests for feline infectious peritonitis in challenging clinical cases. J. Small Anim. Pract. 2011;52: 152–157. doi: 10.1111 / j.1748-5827.2011.01042.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Tsai HY, Chueh LL, Lin CN, Su BL Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan. J. Feline Med. Surg. 2011;13: 74–80. doi: 10.1016 / j.jfms.2010.09.014. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Rohrer C., Suter PF, Lutz H. The diagnosis of feline infectious peritonitis (FIP): A retrospective and prospective study. Kleinterpraxis. 1993;38: 379–389. [Google Scholar]
Riemer F., Kuehner KA, Ritz S., Sauter-Louis C., Hartmann K. Clinical and laboratory features of cats with feline infectious peritonitis – A retrospective study of 231 confirmed cases (2000–2010) J. Feline Med. Surg. 2016;18: 348–356. doi: 10.1177 / 1098612X15586209. [PubMed] [CrossRef] [Google Scholar]
Addie DD, Jarrett JO Use of a reverse-transcriptase polymerase chain reaction for monitoring feline coronavirus shedding by healthy cats. Vet. Rec. 2001;148: 649–653. doi: 10.1136 / vr.148.21.649. [PubMed] [CrossRef] [Google Scholar]
Jinks MR, English RV, Gilger BC Causes of endogenous uveitis in cats presented to referral clinics in North Carolina. Vet. Ophthalmol. 2016;19(Suppl. S1): 30–37. doi: 10.1111 / vop.12324. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Legendre AM, Kuritz T., Galyon G., Baylor VM, Heidel RE Polyprenyl Immunostimulant Treatment of Cats with Presumptive Non-Effusive Feline Infectious Peritonitis in a Field Study. Front. Vet. Sci. 2017;4: 7. doi: 10.3389 / fvets.2017.00007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Fischer Y., Ritz S., Weber K., Sauter-Louis C., Hartmann K. Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Intern. Med. 2011;25: 1270–1276. doi: 10.1111 / j.1939-1676.2011.00806.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Ritz S., Egberink H., Hartmann K. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Intern. Med. 2007;21: 1193–1197. doi: 10.1111 / j.1939-1676.2007.tb01937.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Jepson RE, Syme HM, Vallance C., Elliott J. Plasma asymmetric dimethylarginine, symmetric dimethylarginine, l-arginine, and nitrite / nitrate concentrations in cats with chronic kidney disease and hypertension. J. Vet. Intern. Med. 2008;22: 317–324. doi: 10.1111 / j.1939-1676.2008.0075.x. [PubMed] [CrossRef] [Google Scholar]
Relford R., Robertson J., Clements C. Symmetric Dimethylarginine: Improving the Diagnosis and Staging of Chronic Kidney Disease in Small Animals. Vet. Clin. U.S. Small Anim. Pract. 2016;46: 941–960. doi: 10.1016 / j.cvsm.2016.06.010. [PubMed] [CrossRef] [Google Scholar]
Paltrinieri S., Giraldi M., Prolo A., Scarpa P., Piseddu E., Beccati M., Graziani B., Bo S. Serum symmetric dimethylarginine and creatinine in Birman cats compared with cats of other breeds. J. Feline Med. Surg. 2018;20: 905–912. doi: 10.1177 / 1098612X17734066. [PubMed] [CrossRef] [Google Scholar]
Gil S., Leal RO, McGahie D., Sepúlveda N., Duarte A., Niza MM, Tavares L. Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats, clinical and laboratory evaluation. Res. Vet. Sci. 2014;96: 79–85. doi: 10.1016 / j.rvsc.2013.11.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Addie D. Feline coronavirus infections. In: Green C., editor. Infectious Diseases of the Dog and Cat. Elsevier; Maryland Heights, MO, USA: 2012. pp. 92–108. [Google Scholar]
A 3-month-old Scottish Fold cat with pleural fluid and a low albumin to globulin ratio (A / G ratio) was brought to our small animal hospital. Because feline coronavirus type I (FCoV) RNA was detected in pleural fluid, the cat was pre-diagnosed with an fusion form of feline infectious peritonitis (FIP). After administration of itraconazole and prednisolone, the A / G ratio increased and the pleural fluid almost disappeared. Fecal FCoV levels have temporarily decreased. However, the cat began to show neurological symptoms, and we eventually had to proceed to euthanasia due to the persistent epileptic condition after 38 days of treatment. In conclusion, itraconazole has been shown to be beneficial in the treatment of cats with FIP. However, further investigation of the possible role of itraconazole in the treatment of FIP is needed.
Keywords: feline infectious peritonitis; itraconazole; neurological manifestation; pleural fluid; feline coronavirus type I.
Note: On the Slovak or Czech market, itraconazole contains, for example, drugs called Conisor, Sporanox, Procanazole. They are usually used to treat fungal infections, e.g. nails.
It is typical for a coronavirus that the particular form of the disease it causes depends on the circumstances. He can be compared to a paratrooper who associates with local guerrillas in the body and, in cooperation with them, undertakes destructive sabotage. However, the virus causing infectious feline peritonitis (FIP) is proof that antibodies from an infected animal can also be used to harm.
Has the cheetah coronavirus decimated?
FIP, with its dry and wet forms, is the best known coronavirus disease in animals (Wolf and Gresemer, 1966). However, more than 20 coronavirus strains are known in cats (Knotek, Freedom, 1996).
All felines are susceptible to coronaviruses. But cheetahs are probably the most sensitive. 10,000 years ago, coronavirus FIPs are thought to have decimated the cheetah population to such an extent that cheetahs are genetically significantly less variable than other felines (Knotek, 1996).
Ability to mutate in the gut of cats
In addition to classic FIP, there are agents of enteral coronavirus infection (FECoV - feline enteric coronavirus) and coronavirus-like particles (CoVLP - coronavirus-like particles). The individual strains cross-immunologically react with each other, but differ in both virulence and mortality. Mortality ranges from 0 to 100 %. An interesting feature is their variability and probable mutation ability in the intestines of cats that have undergone viral enteritis.
Up to 7 weeks
The coronavirus enters the cat's body by the nasal or oral route, even indirectly. All you need for the infection is a shared bowl, a transport box or bringing it into your home on your shoes. The feline coronavirus normally stays in the environment for up to 7 weeks.
After entering the mucosa of the upper respiratory tract or the oral cavity, the virus replicates in the epithelium of the tonsils and small intestine. Secondary infection occurs in enterocytes, but also in other visceral organs (liver, spleen, kidneys and lymph nodes). Antibodies appear 7. − 10. the day after infection, but excretion of the virus by oronasal secretion occurs on day 2 after infection.
Macrophages as a means of transport
However, antibodies do not protect against FIP, vice versa they form complexes with the virus, allowing the virus to enter cells, including macrophages. Damaged macrophages then spread the virus around the body. This condition is exacerbated by stress, immunosuppressive factors (corticoids?) And especially by concomitant feline infectious leukosis (FeLV).
The incubation period depends on many factors, especially the active cell-mediated immune response and its ability to remove infected macrophages from the bloodstream.
Influence of interferon suppression on disease development
Macrophages are involved in the formation of perivascular lesions and the release of inflammatory mediators during the course of the disease. Vascular endothelial damage, blood clotting disorders, thrombocytopenia and excessive vascular permeability occur. Due to the action of prostaglandin E2 (PGE2) from damaged macrophages and neutrophils occurs interferon suppressionwhich normally prevents the virus from multiplying. Under these conditions, however, the virus uses the macrophages of the infected organism for its replication and transport throughout the body. The most massive manifestations of the virus take place in organs that contain large numbers of macrophages - in the liver, spleen, lymph nodes (Knotek, Freedom, 1996).
The effect of interferon suppression on disease development corresponds to my experience with the control of (not only) coronavirus diseases impulse therapywhose principle is stimulation of interferon by the body itself, ie endogenous. This method is both cheaper than the administration of exogenous interferon does not cause the side effects typical of exogenous interferon.
The clinical picture of FIP depends on the form of the disease
Clinical manifestations of 2 main forms of FIP - exudative and non-fusible (ie dry) - is different. In the first case (wet form), fibrin exudate is present on the peritoneum and there is a massive thickening of the mesentery with a watery or gelatinous consistency. The omentum forms a contracted formation in the cranial part of the abdomen. Similar fibrinous effusions may also occur in the thoracic cavity and pericardium, corresponding to the pattern of the disease in humans.
In the dry form, inflammatory diseases of the liver, spleen, lungs, CNS and eyes occur. Hyperbilirubinemia and jaundice may occur in the terminal stages.
Beware of seemingly cured carriers
Incubation time depends on the strain of FIP, the type and massiveness of exposure, the health status and age of the patient and his immunocompetence, especially mediated cellular immunity. It can move from 3-6 weeks to 6 months. A seemingly cured patient can be a hidden vector of the disease.
An intranasal vaccine was used to vaccinate cats, which stimulated the production of local mucosal immunity. However, it is no longer available in the Czech Republic and possibly in the European Union.
MVDr. Zdeněk Cvrček Veterinary clinic and clinic Liberec
Gilead said the decision to develop remdesivir was made after it was shown to be "more effective" than GS-441524 in certain key areas. Jessica Glenza@JessicaGlenza Photo: Mike Blake / Reuters Tuesday 4 August 2020 02.07 EDT
Activists are urging the pharmaceutical company Gilead Sciences to study a drug for the treatment of Covid-19, which has shown promise in the treatment of feline coronavirus.
GS-441524 is chemically related to remdesivir, an antiviral drug also manufactured by Gilead, and one of the few treatments that successfully shortens the recovery time after Covid-19.
GS-441524 attracted attention with promising results in the treatment of another coronavirus disease - feline infectious peritonitis (FIP). The drug has become a major black market item with unapproved treatment for the disease, which until recently was generally considered incurable and fatal in cats.
In a letter to leaders of four government agencies currently developing treatment and vaccine for Covid-19, the left-wing Public Citizen group called on Gilead to work together to begin developing the drug.
The group also accused Gilead of deciding to develop remdesivir, which is much further in the clinical testing process than GS-441524, as it would remain in patent protection for longer and therefore generate greater profits.
"It is sadly predictable that the company is responding to a global pandemic by trying to market only those drugs that maximize its profits," said Dr. Michael Abrams, Public Citizen Health Research Research Fellow and lead author of the paper.
"It is alarming that federal scientists and the Trump's regulatory administration are showing a willingness to partner with Gilead in a decision that runs counter to the government's main imperative of improving public health during this global crisis," Abrams said.
Gilead specializes in antiviral drugs and has been criticized for its pricing policy in the past. A patented hepatitis C drug costs $ 1,000 per pill in the United States or $ 84,000 for the entire treatment. And Truvada, an HIV prevention drug that could significantly reduce transmission, can cost up to $ 20,000 a year in the United States.
However, not everyone agrees that price alone is the driving force behind Gilead's decision. Derek Lowe is a drug discovery scientist and author of In the Pipeline, a blog that focuses on early drug development. Lowe said that remdesivir could only be useful for a relatively short period of time until a successful vaccine was developed, and that GS-441524 lagged behind remdesivir by years.
“Monoclonal antibodies and vaccines are, in my opinion (and not just my opinion), the answer to this pandemic,” Lowe said. Once these treatments become available, molecular-based antivirals like remdesivir and GS-441524 will become less valuable and necessary.
Remdesivir was readily available for human use because Gilead hoped to develop a drug to treat Ebola. And even though treatment of the virus failed, remdesivir had a "defined dose and safety profile," according to researchers at the National Institutes of Health.
“That’s what’s driving Gilead’s decisions—they know that remdesivir is their silver lining, and that pouring their (large but finite) resources into another compound to catch up might be a bad move,” Lowe said. “It’s possible that by the time it’s ready to launch, no one will be interested.”
A Gilead spokesman said the decision to develop remdesivir was made when it appeared that in some key areas "more effective” as GS-441524, and thus is a better candidate for potential treatment of Covid-19.
"The ability to rapidly progress clinical trials of remdesivir, given the urgency of the global pandemic, was a determining factor in this decision," the spokesperson added.